Merck Heart Drug Tredaptive Raises Side Effects in Study

Merck & Co.’s cholesterol drug Tredaptive, pulled from the market earlier this year, increased side effects like bleeding and infections and didn’t help patients, according to results of a clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.